title: Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
abstract: Human lymphoblastoid interferon (IFN)-alpha was administered intramuscularly at doses of 5 megaunits/day 5 to 7 days a week to 32 advanced renal cell carcinoma patients. To augment the antitumor effect of IFN, cimetidine was also administered orally in doses oi 800 mg/day. This combination therapy resulted in a complete response (CR) in 6 patients (19%), a partial response (PR) in 7 (22%), a stable disease (SD) in 11 (34%), and a progressive disease (PD) in 8 (25%). The response rate (CR+PR) was 41%. The pulmonary metastases were more receptive to IFN therapy than those at other sites. The median times to response were 2 months for PR, and 4.5 months for CR. The survival of the responder patients was significantly longer than the nonresponder patients. These results suggest that IFN-alpha and cimetidine combination therapy may be of use in the management of advanced renal cell carcinoma.
authors.affiliation: Department of Urology, Center for Adult Diseases, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kinouchi
authors.forename: N
authors.initials: N
authors.lastname: Meguro
authors.forename: O
authors.initials: O
authors.lastname: Maeda
authors.forename: S
authors.initials: S
authors.lastname: Saiki
authors.forename: M
authors.initials: M
authors.lastname: Kuroda
authors.forename: M
authors.initials: M
authors.lastname: Usami
authors.forename: T
authors.initials: T
authors.lastname: Kotake
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D002927:Cimetidine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009392:Nephrectomy; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D016898:Interferon-alpha; D002927:Cimetidine
keywords: cimetidine; interferon-alpha; renal cell carcinoma